Folsyrasynteshämmare

Folsyrasynteshämmare are a class of drugs that inhibit the synthesis of folic acid, also known as vitamin B9. Folic acid is essential for cell growth and division, and its synthesis is a vital process for many organisms, including bacteria and protozoa. By blocking this pathway,Folsyrasynteshämmare can effectively prevent the proliferation of these pathogens.

The primary mechanism of action for most Folsyrasynteshämmare involves targeting enzymes within the folic acid synthesis pathway. A common target is dihydropteroate synthase (DHPS), an enzyme that catalyzes an early step in the pathway. Drugs like sulfonamides act as competitive inhibitors of DHPS, mimicking the natural substrate and preventing its conversion. Another crucial enzyme targeted is dihydrofolate reductase (DHFR), which converts dihydrofolate to tetrahydrofolate, the active form of folic acid. Trimethoprim is a well-known inhibitor of DHFR.

Folsyrasynteshämmare are widely used as antimicrobial agents. They are particularly effective against a range of bacteria and are often used in combination therapies to enhance efficacy and reduce the development of resistance. For example, the combination of sulfamethoxazole (a sulfonamide) and trimethoprim is a frequently prescribed antibiotic. These drugs are also used in the treatment of certain parasitic infections, such as malaria and toxoplasmosis, where the folic acid synthesis pathway differs slightly from that in humans, allowing for selective toxicity.

The development of resistance to Folsyrasynteshämmare can occur through various mechanisms, including mutations in the target enzymes that reduce drug binding, or the acquisition of alternative metabolic pathways by the pathogen. Therefore, judicious use and combination therapies are important strategies to mitigate resistance.

---